Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 98 of the 113 references it cites were found in a registry or an index; 5 of the 59 sources its claims cite were checked for support.

Economic impact of medication non-adherence by disease groups: a systematic review

Open access
Cutler, Rachelle Louise, Fernandez-Llimos, Fernando, Frommer, Michael, Benrimoj, Charlie, Garcia-Cardenas, Victoria · 2018 · BMJ Open

Abstract

OBJECTIVE: To determine the economic impact of medication non-adherence across multiple disease groups. DESIGN: Systematic review. EVIDENCE REVIEW: A comprehensive literature search was conducted in PubMed and Scopus in September 2017. Studies quantifying the cost of medication non-adherence in relation to economic impact were included. Relevant information was extracted and quality assessed using the Drummond checklist. RESULTS: Seventy-nine individual studies assessing the cost of medication non-adherence across 14 disease groups were included. Wide-scoping cost variations were reported, with lower levels of adherence generally associated with higher total costs. The annual adjusted disease-specific economic cost of non-adherence per person ranged from $949 to $44 190 (in 2015 US$). Costs attributed to 'all causes' non-adherence ranged from $5271 to $52 341. Medication possession ratio was the metric most used to calculate patient adherence, with varying cut-off points defining non-adherence. The main indicators used to measure the cost of non-adherence were total cost or total healthcare cost (83% of studies), pharmacy costs (70%), inpatient costs (46%), outpatient costs (50%), emergency department visit costs (27%), medical costs (29%) and hospitalisation costs (18%). Drummond quality assessment yielded 10 studies of high quality with all studies performing partial economic evaluations to varying extents. CONCLUSION: Medication non-adherence places a significant cost burden on healthcare systems. Current research assessing the economic impact of medication non-adherence is limited and of varying quality, failing to provide adaptable data to influence health policy. The correlation between increased non-adherence and higher disease prevalence should be used to inform policymakers to help circumvent avoidable costs to the healthcare system. Differences in methods make the comparison among studies challenging and an accurate estimation of true magnitude of the cost impossible. Standardisation of the metric measures used to estimate medication non-adherence and development of a streamlined approach to quantify costs is required. PROSPERO REGISTRATION NUMBER: CRD42015027338.

Overview

CoChat Summary

## TL;DR

This systematic review found that medication non-adherence is generally associated with higher healthcare costs across 14 disease groups, but the reported costs varied widely and could not be meaningfully pooled because of heterogeneity. Across 79 included studies, the adjusted annual disease-specific cost of non-adherence per person ranged from $949 to $44,190, and the authors concluded that standardised adherence and cost measures are needed.

## Key findings

  • The review included 79 individual studies across 14 disease groups; search strategies retrieved 2768 records, 289 were full-text reviewed, and 79 were included.
  • Reported annual adjusted disease-specific economic cost of non-adherence per person ranged from $949 to $44,190 (2015 US$); costs attributed to “all causes” non-adherence ranged from $5271 to $52,341.
  • Across studies reporting total or total healthcare costs, 39 studies (49%) found non-adherence costs were greater than adherence costs, while 11 studies (15%) found the opposite.
  • The most-used adherence metric was medication possession ratio (MPR), reported in 51 studies (63%); the next most common was proportion of days covered (PDC) at 11%.
  • Quality assessment found 10 high-quality, 59 medium-quality, and 10 low-quality studies; no full economic evaluation was conducted in any included study.

## Methods

  • Design: Systematic review conducted according to PRISMA and registered in PROSPERO (CRD42015027338).
  • Data/sample: Searches were run in PubMed and Scopus in September 2017, with no publication date or language restrictions; included studies had to report the monetary cost of medication non-adherence for any disease state and provide original data.
  • Main analysis: Two reviewers appraised studies using a modified Drummond checklist; costs were converted to 2015 US$, extracted by outcome indicator, and the authors attempted but could not perform a meta-analysis because of heterogeneity and missing statistical parameters.

## Limitations

  • The paper states that a meta-analysis could not be performed because of heterogeneity in study design and lack of required statistical parameters, particularly standard deviations.
  • The authors note that differences in methodological strategies, adherence definitions, and cost indicators made comparison across studies difficult and limited estimation of the true magnitude of costs.
  • Evident from the text: the evidence base was dominated by US studies (66 of 79; 83%), and many studies were partial economic evaluations rather than full economic evaluations, which limits generalisability and comparability.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1136/bmjopen-2017-016982

Cites

98 of 98 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram. The PRISMA diagram details the search and selection process applied during the overview. The search yielded a total of 2768 citations. Studies were selected based on the inclusion criteria; studies reporting the cost of medication non-adherence using original cost data. Intervention studies were required to report baseline data. Seventy-nine original studies met the inclusion criteria.
Figure 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram. The PRISMA diagram details the search and selection process applied during the overview. The search yielded a total of 2768 citations. Studies were selected based on the inclusion criteria; studies reporting the cost of medication non-adherence using original cost data. Intervention studies were required to report baseline data. Seventy-nine original studies met the inclusion criteria.CC BY-NC · PubMed Central
Figure 2 Annual adjusted medication non-adherence costs per patient per year. Encompasses the minimum, maximum and IQR of adjusted annual costs incurred by patients across disease groups where three or more studies were included for review. Gastrointestinal only included three studies limiting the range of costs. All-cause costs encompass non-adherence costs incurred in mixed disease state studies, taking into account other confounding factors such as comorbidities.
Figure 2 Annual adjusted medication non-adherence costs per patient per year. Encompasses the minimum, maximum and IQR of adjusted annual costs incurred by patients across disease groups where three or more studies were included for review. Gastrointestinal only included three studies limiting the range of costs. All-cause costs encompass non-adherence costs incurred in mixed disease state studies, taking into account other confounding factors such as comorbidities.CC BY-NC · PubMed Central
Figure 3 Annual unadjusted medication non-adherence costs per patient per year. Encompasses the minimum, maximum and IQR of unadjusted annual costs incurred by patients across disease groups where three or more studies were included for review. Epilepsy and addiction only included three studies limiting the range of costs. All-cause costs encompass non-adherence costs incurred in mixed disease state studies, taking into account other confounding factors such as comorbidities.
Figure 3 Annual unadjusted medication non-adherence costs per patient per year. Encompasses the minimum, maximum and IQR of unadjusted annual costs incurred by patients across disease groups where three or more studies were included for review. Epilepsy and addiction only included three studies limiting the range of costs. All-cause costs encompass non-adherence costs incurred in mixed disease state studies, taking into account other confounding factors such as comorbidities.CC BY-NC · PubMed Central

Verification

Claims the paper makes

4 Valid · 0 Not valid · 58 Not checked · 72 Own results and interpretations

67 more claims

Create a free account to see all 134 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 43
  • Probably not a substantial claim. 28
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 113 references

Cited by

See all 900

Metadata

Authors
Cutler, R. L., Fernandez-Llimos, F., Frommer, M., Benrimoj, C., & Garcia-Cardenas, V.
Affiliations
  • University of Technology Sydney (AU)
  • Department of Social Pharmacy Faculty of Pharmacy, Research Institute for Medicines (iMed.ULisboa), University of Lisbon, Lisbon, Portugal
  • The University of Sydney (AU)
  • Graduate School of Health, University of Technology Sydney, Sydney, New South Wales, Australia
Corresponding author
Cutler, Rachelle Louise
Venue
BMJ Open
Publisher
BMJ
Published
2018-01
Volume
8
Issue
1
Pages
e016982
ISSN
2044-6055 (ISSN-L)
OpenAlex
W2790318238
Cited by
900
References
113
Citations by year
2026: 83 · 2025: 111 · 2024: 159 · 2023: 134 · 2022: 112 · 2021: 124 · 2020: 91 · 2019: 68 · 2018: 16
FWCI
16.46
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • BMJ Open (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • OPUS - Open Publications of UTS Scholars (University of Technology Sydney) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
Australian Government
Topics
  • Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Economic and Financial Impacts of Cancer
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
Keywords
medication non-adherence, economic burden, health care costs, medication possession ratio, adherence measurement, health policy
MeSH terms
Cost-Benefit Analysis, Disease, Drug Therapy, Humans, Drug Monitoring, Cost of Illness

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Economic impact of medication non-adherence by disease groups: a systematic review. https://app.cochat.ai/papers/10.1136/bmjopen-2017-016982
The paper
Cutler, R. L., Fernandez-Llimos, F., Frommer, M., Benrimoj, C., & Garcia-Cardenas, V. (2018). Economic impact of medication non-adherence by disease groups: a systematic review. BMJ Open. https://doi.org/10.1136/bmjopen-2017-016982

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.